Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 171 Cr.
- Current Price ₹ 37.5
- High / Low ₹ 99.7 / 35.0
- Stock P/E 305
- Book Value ₹ 11.9
- Dividend Yield 0.00 %
- ROCE 7.73 %
- ROE 3.22 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.15 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 33.4%
- Company has a low return on equity of 11.3% over last 3 years.
- Earnings include an other income of Rs.5.45 Cr.
- Promoter holding has decreased over last 3 years: -17.0%
- Working capital days have increased from 214 days to 382 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Hotels & Restaurants Industry: Hotels
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.77 | 20.71 | 57.66 | 74.11 | 61.42 | 49.79 | |
0.06 | 0.07 | 0.09 | 0.13 | 0.10 | 0.12 | 0.21 | 47.00 | 25.37 | 51.42 | 65.39 | 55.62 | 45.03 | |
Operating Profit | -0.06 | -0.07 | -0.09 | -0.13 | -0.10 | -0.12 | -0.21 | 2.77 | -4.66 | 6.24 | 8.72 | 5.80 | 4.76 |
OPM % | 5.57% | -22.50% | 10.82% | 11.77% | 9.44% | 9.56% | |||||||
0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.20 | -3.85 | 0.22 | 0.14 | 3.62 | 5.45 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15 | 1.97 | 1.89 | 2.85 | 4.96 | 6.66 |
Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.40 | 0.34 | 0.93 | 1.45 | 1.36 |
Profit before tax | -0.01 | -0.07 | -0.10 | -0.13 | -0.10 | -0.12 | -0.05 | 0.81 | -10.88 | 4.23 | 5.08 | 3.01 | 2.19 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.39% | 51.50% | |
-0.01 | -0.07 | -0.10 | -0.13 | -0.10 | -0.12 | -0.05 | 0.81 | -10.89 | 4.23 | 5.06 | 1.46 | 0.56 | |
EPS in Rs | -0.03 | -0.19 | -0.27 | -0.36 | -0.27 | -0.33 | -0.14 | 2.22 | -3.18 | 1.24 | 1.48 | 0.32 | 0.13 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 44% |
TTM: | -34% |
Compounded Profit Growth | |
---|---|
10 Years: | 37% |
5 Years: | 99% |
3 Years: | 30% |
TTM: | -86% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 50% |
3 Years: | 13% |
1 Year: | -39% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 11% |
Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 34.23 | 34.23 | 34.23 | 45.54 | 45.54 |
Reserves | -0.22 | -0.29 | -0.39 | -0.52 | -4.12 | -4.25 | -4.30 | 27.19 | -14.28 | -10.05 | 6.13 | 4.86 | 8.58 |
0.13 | 0.15 | 0.26 | 0.40 | 0.48 | 0.60 | 0.64 | 13.74 | 15.43 | 16.73 | 51.96 | 63.46 | 68.51 | |
0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.02 | 0.03 | 6.91 | 4.47 | 8.53 | 7.98 | 12.14 | 14.03 | |
Total Liabilities | 3.55 | 3.51 | 3.53 | 3.53 | 0.00 | 0.01 | 0.01 | 51.48 | 39.85 | 49.44 | 100.30 | 126.00 | 136.66 |
3.51 | 3.51 | 3.50 | 3.50 | 0.00 | 0.00 | 0.00 | 17.36 | 15.11 | 15.33 | 23.81 | 21.66 | 21.23 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.59 | 13.72 | 13.22 | 12.72 | 18.03 | 18.09 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.19 | 0.19 | 7.99 | 9.56 | 9.56 |
0.04 | 0.00 | 0.03 | 0.03 | 0.00 | 0.01 | 0.01 | 20.52 | 10.83 | 20.70 | 55.78 | 76.75 | 87.78 | |
Total Assets | 3.55 | 3.51 | 3.53 | 3.53 | 0.00 | 0.01 | 0.01 | 51.48 | 39.85 | 49.44 | 100.30 | 126.00 | 136.66 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.07 | -0.06 | -0.09 | -0.13 | -0.10 | -0.12 | -0.21 | 5.96 | 0.52 | 3.47 | 8.33 | 26.09 | |
0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.67 | -0.56 | 0.59 | -14.09 | -7.26 | |
-0.13 | 0.02 | 0.12 | 0.14 | 0.08 | 0.13 | 0.20 | -1.28 | -0.73 | -3.23 | 4.93 | -19.19 | |
Net Cash Flow | 0.05 | -0.04 | 0.02 | 0.01 | -0.03 | 0.01 | 0.00 | 1.01 | -0.78 | 0.82 | -0.83 | -0.36 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 51.63 | 84.07 | 81.53 | 79.93 | 104.59 | |||||||
Inventory Days | 56.98 | 25.01 | 12.59 | 16.36 | 19.94 | |||||||
Days Payable | 70.35 | 79.21 | 59.29 | 13.72 | 28.24 | |||||||
Cash Conversion Cycle | 38.26 | 29.87 | 34.84 | 82.57 | 96.28 | |||||||
Working Capital Days | 80.08 | 69.79 | 50.83 | 208.23 | 381.70 | |||||||
ROCE % | -1.72% | -1.99% | -2.85% | -3.70% | -5.68% | 8.80% | -12.01% | 16.04% | 12.65% | 7.73% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper publications of unaudited financial results for the quarter and half year ended 30th September 2024.
-
Announcement under Regulation 30 (LODR)-Raising of Funds
15 Nov - Board approved financial results and rights issue.
-
.Pursuant To Regulation 33 Of SEBI (LODR) Regulations 2015, The Board Meeting Held On Today I.E, 14-11-2024 Has Approved The Unaudited Standalone And Consolidated Results For The Quarter Ended 30-09-2024.
15 Nov - Board approved unaudited financial results and rights issue.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14-08-2024 Is Attached.
14 Nov - Approval of financial results and rights issue.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14-08-2024 Is Attached.
14 Nov - Approved financial results and rights issue proposal.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
IBL has multiple business units managed by an
independent team of field experts. It operates
in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure